



WORLD ACADEMIC FRONTIERS  
OF MEDICINE AND PHARMACY  
世界医药学研究前沿丛书

# Pharmacokinetics

## 药代动力学

"世界医药学研究前沿丛书"编委会 编

THE EDITORIAL BOARD OF  
WORLD ACADEMIC FRONTIERS  
OF MEDICINE AND PHARMACY



世界图书出版公司

## EDITORIAL BOARD

- Prof. James CS Chim, Clinical Professor, Department of Medicine, University of Hong Kong, China
- Dr. Jürgen Kasper, Unit of Health Science and Education and Institute of Communication in Medicine. Hamburg University, Germany
- Prof. Junming Liao, Department of Biochemistry & Molecular Biology and Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA
- Dr. Marc Afilalo, Emergency Multidisciplinary Research Unit, McGill University, Canada
- Prof. Trond Buanes, Department of Gastroenterological Surgery, Division of Cancer, Surgery and Transplantation, Institute of Clinical Medicine, Faculty of Medicine, Oslo University Hospital, Oslo N-0424, Norway
- Dr. Andrew M. Tan, Center for Neuroscience and Regeneration Research Department of Neurology Yale University School of Medicine, USA
- Dr. Kambiz N. Alavian, School of Medicine Section of Endocrinology and Metabolism Department of Internal Medicine Yale University, USA
- Dr. Jeremy R. Porter, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harvard University, 25 Shattuck Street, Boston, MA 02115, USA

ISBN 978-7-5192-5872-6



9 787519 258726 >

定价：598.00 元



WORLD ACADEMIC FRONTIERS  
OF MEDICINE AND PHARMACY  
世界医药学研究前沿丛书

# Pharmacokinetics

## 药代动力学

“世界医药学研究前沿丛书”编委会 编  
THE EDITORIAL BOARD OF  
WORLD ACADEMIC FRONTIERS  
OF MEDICINE AND PHARMACY

中国出版集团公司

世界医药学研究前沿丛书

广州·上海·西安·北京

47218

## 图书在版编目 (CIP) 数据

药代动力学：英文 / “世界医药学研究前沿丛书”

编委会编. — 广州：世界图书出版广东有限公司, 2018. 12

ISBN 978-7-5192-5872-6

I. ①药… II. ①世… III. ①药物代谢动力学—英文  
IV. ①R969.1

中国版本图书馆CIP数据核字(2019)第006648号

---

书 名	药代动力学 YAODAI DONGLIXUE
编 者	“世界医药学研究前沿丛书”编委会
责任编辑	康琬娟 张柏登
责任技编	刘上锦
出版发行	世界图书出版广东有限公司
地 址	广州市海珠区新港西路大江冲25号
邮 编	510300
电 话	(020) 84460408
网 址	<a href="http://www.gdst.com.cn/">http://www.gdst.com.cn/</a>
邮 箱	wpc_gdst@163.com
经 销	新华书店
印 刷	广州市迪桦彩印有限公司
开 本	787 mm×1092 mm 1/16
印 张	54.75
字 数	1320千字
版 次	2019年3月第1版 2019年3月第1次印刷
国际书号	ISBN 978-7-5192-5872-6
定 价	598.00元

---

版权所有 翻印必究  
(如有印装错误, 请与出版社联系)

# Preface

Pharmacokinetics, sometimes abbreviated as PK, is a branch of pharmacology dedicated to determining the fate of substances administered to a living organism. The substances of interest include any chemical xenobiotic such as: pharmaceutical drugs, pesticides, food additives, cosmetics, etc. It attempts to analyze chemical metabolism and to discover the fate of a chemical from the moment that it is administered up to the point at which it is completely eliminated from the body. Pharmacokinetics is the study of how an organism affects a drug, whereas pharmacodynamics (PD) is the study of how the drug affects the organism. Both together influence dosing, benefit, and adverse effects, as seen in PK/PD models.<sup>1</sup>

Pharmacokinetics describes how the body affects a specific xenobiotic/chemical after administration through the mechanisms of absorption and distribution, as well as the metabolic changes of the substance in the body (e.g. by metabolic enzymes such as cytochrome P450 or glucuronosyltransferase enzymes), and the effects and routes of excretion of the metabolites of the drug. Pharmacokinetic properties of chemicals are affected by the route of administration and the dose of administered drug. These may affect the absorption rate.

In the present book, thirty typical literatures about Pharmacokinetics published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on pharmaceutical care, pharmaceuticals, pharmacodynamics, pharmacoepidemiology, pharmacology and Neuroimaging, etc. We hope this book can demonstrate advances in biosensor as well as give references to the researchers, students and other related people.

<sup>1</sup><https://en.wikipedia.org/wiki/Pharmacokinetics>.

## Editorial Board

- 1) 詹楚生教授，临床教授，医学系，香港大学，中国  
Prof. James CS Chim, Clinical Professor, Department of Medicine, University of Hong Kong, China
- 2) 尤尔根·卡斯帕博士，卫生科学与教育部和医学传播研究所，汉堡大学，德国  
Dr. Jürgen Kasper, Unit of Health Science and Education and Institute of Communication in Medicine, Hamburg University, Germany
- 3) 廖俊明教授，生物化学与分子生物学学系及杜兰癌症中心，杜兰大学医学院，新奥尔良，美国  
Prof. Junming Liao, Department of Biochemistry & Molecular Biology and Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA
- 4) 马克·阿菲拉洛博士，紧急多学科研究小组，麦吉尔大学，加拿大  
Dr. Marc Afilalo, Emergency Multidisciplinary Research Unit, McGill University, Canada
- 5) 特朗德·比阿内教授，胃肠外科系，癌症、外科和移植科，临床医学研究所，医学院，奥斯陆大学医院，奥斯陆，挪威  
Prof. Trond Buanes, Department of Gastroenterological Surgery, Division of Cancer, Surgery and Transplantation, Institute of Clinical Medicine, Faculty of Medicine, Oslo University Hospital, Oslo N-0424, Norway
- 6) 安德鲁·M·谭博士，神经科学与再生研究中心神经内科，耶鲁大学医学院，美国  
Dr. Andrew M. Tan, Center for Neuroscience and Regeneration Research Department of Neurology Yale University School of Medicine, USA

- 7) 坎比兹·N·阿拉维教授，医学院，内分泌代谢科内科，耶鲁大学，美国  
Dr. Kambiz N. Alavian, School of Medicine Section of Endocrinology and Metabolism Department of Internal Medicine Yale University, USA
- 8) 杰里米·R·波特博士，生物化学与分子药理学学系，哈佛大学医学院，哈佛大学，波士顿市，美国  
Dr. Jeremy R. Porter, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harvard University, 25 Shattuck Street ,Boston, MA 02115, USA

## Selected Author

**Todd Defor**, Division of Hematology/Oncology/Transplantation, University of Minnesota, Minneapolis, USA

**Zoe Oesterreicher**, Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

**Virginia R Fajt**, Large Animal Clinical Sciences, Texas A&M University College of Veterinary Medicine & Biomedical Sciences, College Station, USA

**Vikram Malhi**, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA

**Meredyth L Jones**, Large Animal Clinical Sciences, Texas A&M University College of Veterinary Medicine & Biomedical Sciences, College Station, USA

**Toshiaki Komatsu**, Department of Pharmacy, Kitasato University Hospital, Sagamihara, Japan

**Kathrin Buntenkötter**, Institute of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine Hannover Foundation, Hannover, Germany

**Noriko Kohyama**, Division of Clinical Pharmacy, Department of Pharmacotherapeutics, Showa University School of Pharmacy, Tokyo, Japan

**Marek Koziński**, Department of Principles of Clinical Medicine, Nicolaus Copernicus University, Collegium Medicum, 9 Skłodowskiej-Curie Street, 85-094 Bydgoszcz, Poland

**N. P. Riksen**, Department of Pharmacology-Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands

---

# Contents

<b>Chapter 1</b> .....	<b>1</b>
Pharmacokinetics of Ranitidine in Preterm and Term Neonates with Gastroesophageal Reflux <i>by Ismael Lares Asseff, Graciela Benitez Gaucin, Hugo Juárez Olguín, et al.</i>	
<b>Chapter 2</b> .....	<b>15</b>
Effects of CYP3A5 Polymorphism on the Pharmacokinetics of a Once-Daily Modified-Release Tacrolimus Formulation and Acute Kidney Injury in Hematopoietic Stem Cell Transplantation <i>by Takaya Yamashita, Naohito Fujishima, Masatomo Miura, et al.</i>	
<b>Chapter 3</b> .....	<b>33</b>
Antiplasmodial Activity, <i>in Vivo</i> Pharmacokinetics and Anti-Malarial Efficacy Evaluation of Hydroxypyridinone Hybrids in a Mouse Model <i>by Ntokozo S. Dambuza, Peter Smith, Alicia Evans, et al.</i>	
<b>Chapter 4</b> .....	<b>49</b>
Psychomotor Effect Differences between l-Methamphetamine and d-Methamphetamine are Independent of Murine Plasma and Brain Pharmacokinetics Profiles <i>by Tetsuya Nishimura, Kazue Takahata, Yuri Kosugi, et al.</i>	
<b>Chapter 5</b> .....	<b>59</b>
A Randomised Trial Comparing the Pharmacokinetics and Safety of the Biosimilar CT-P6 with Reference Trastuzumab <i>by Francisco J. Esteva, Justin Stebbing, Rebecca N. Wood-Horral, et al.</i>	

<b>Chapter 6</b> .....	<b>81</b>
<i>In Vivo</i> Therapeutic Efficacy and Pharmacokinetics of Colistin Sulfate in an Experimental Model of Enterotoxigenic <i>Escherichia coli</i> Infection in Weaned Pigs <i>by Mohamed Rhouma, Francis Beaudry, William Thériault, et al.</i>	
<b>Chapter 7</b> .....	<b>107</b>
Integration of Pharmacometabolomics with Pharmacokinetics and Pharmacodynamics: Towards Personalized Drug Therapy <i>by Vasudev Kantae, Elke H. J. Krekels, Michiel J. Van Esdonk, et al.</i>	
<b>Chapter 8</b> .....	<b>131</b>
A Multicenter, Randomized, Open-Label, Active-Comparator Trial to Determine the Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen for Treatment of Fever in Hospitalized Pediatric Patients <i>by Samia N. Khalil, Barry J. Hahn, Corrie E. Chumpitazi, et al.</i>	
<b>Chapter 9</b> .....	<b>157</b>
A Clinical Drug–Drug Interaction Study to Evaluate the Effect of a Proton-Pump Inhibitor, A Combined P-Glycoprotein/Cytochrome 450 Enzyme (CYP)3A4 inhibitor, and a CYP2C9 Inhibitor on the Pharmacokinetics of Vismodegib <i>by Vikram Malhi, Dawn Colburn, Sarah J. Williams, et al.</i>	
<b>Chapter 10</b> .....	<b>177</b>
Safety, Tolerability and Pharmacokinetics of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Japanese Patients with Advanced Solid Tumours: A Phase I Study <i>by Hideo Saka, Chiyoe Kitagawa, Yoshihito Kogure, et al.</i>	
<b>Chapter 11</b> .....	<b>203</b>
Pharmacokinetics of Carfilzomib In Patients with Advanced Malignancies and Varying Degrees of Hepatic Impairment: An Open-Label, Single-Arm, Phase 1 Study <i>by Jennifer Brown, Ruth Plummer, Todd M. Bauer, et al.</i>	
<b>Chapter 12</b> .....	<b>227</b>

---

I-124 Codrituzumab Imaging and Biodistribution in Patients with  
Hepatocellular Carcinoma  
*by Jorge A. Carrasquillo, Joseph A. O'Donoghue, Volkan Beylertgil, et al.*

**Chapter 13.....253**

Synovial Fluid Pharmacokinetics of Tulathromycin, Gamithromycin and  
Florfenicol after a Single Subcutaneous Dose in Cattle  
*by Meredyth L Jones, Kevin E Washburn, Virginia R Fajt, et al.*

**Chapter 14.....269**

Population Pharmacokinetics of Haloperidol in Terminally ILL Adult Patients  
*by L. G. Franken, R. A. A. Mathot, A. D. Masman, et al.*

**Chapter 15.....285**

Development and Validation of a LC–MS/MS Method for Quantification of  
Hetrombopag for Pharmacokinetics Study  
*by Tao Chen, Zhonghua Chen, Suxing Zhang, et al.*

**Chapter 16.....301**

Population Pharmacokinetics and Optimization of the Dosing Regimen of  
Digoxin in Adult Patients  
*by Toshiaki Komatsu, Mami Morita, Futaba Miyaji, et al.*

**Chapter 17.....317**

Pharmacokinetics and *in Vitro* Efficacy of Salicylic Acid after Oral  
Administration of Acetylsalicylic Acid in Horses  
*by Kathrin Buntenkötter, Maren Osmers, Ina Schenk, et al.*

**Chapter 18.....337**

The Pharmacokinetics of Mianserin Suppositories for Rectal  
Administration in Dogs and Healthy Volunteers:  
A Pilot Study  
*by Shuichi Nawata, Noriko Kohyama, Toshinori Yamamoto, et al.*

**Chapter 19.....355**

The Effect of Dipyridamole on the Pharmacokinetics of Metformin:  
A Randomized Crossover Study in Healthy Volunteers

*by S. El Messaoudi, F. G. Russel, N. P. Riksen, et al.*

**Chapter 20.....369**

Pharmacokinetics of Doripenem in Plasma and Epithelial Lining Fluid (ELF):  
Comparison of Two Dosage Regimens

*by Zoe Oesterreicher, Iris Minichmayr, Markus Zeitlinger, et al.*

**Chapter 21.....383**

Brivaracetam Population Pharmacokinetics in Children with Epilepsy Aged 1  
Month to 16 Years

*by Rik Schoemaker, Janet R Wade and Armel Stockis*

**Chapter 22.....401**

The Understanding of Core Pharmacological Concepts among Health Care  
Students in Their Final Semester

*by Patrik Aronsson, Shirley Booth, Staffan Hägg, et al.*

**Chapter 23.....419**

Angiotensin Converting Enzyme Inhibitors (ACEI) and Doxorubicin  
Pharmacokinetics in Women Receiving Adjuvant Breast Cancer Treatment

*by Anne Blaes, Daniel Duprez, Todd Defor, et al.*

**Chapter 24.....435**

Smoking and Antidepressants Pharmacokinetics: A Systematic Review

*by Pedro Oliveira, Joana Ribeiro and Helena Donato*

**Chapter 25.....451**

Influence of Morphine on Pharmacokinetics and Pharmacodynamics of  
Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION):  
Study Protocol for a Randomized Controlled Trial

*by Jacek Kubica, Piotr Adamski, Małgorzata Ostrowska, et al.*

**Chapter 26.....465**

*In Vitro* Studies and *In Silico* Predictions of Fluconazole and CYP2C9 Genetic  
Polymorphism Impact on Siponimod Metabolism and Pharmacokinetics

*by Yi Jin, Hubert Borell, Anne Gardin, et al.*

---

<b>Chapter 27</b> .....	<b>489</b>
Pharmacokinetics of Mefloquine and Its Effect on Sulfamethoxazole and Trimethoprim Steady-State Blood Levels in Intermittent Preventive Treatment (IPTp) of Pregnant HIV-Infected Women in Kenya <i>by Michael Green, Kephias Otieno, Abraham Katana, et al.</i>	
<b>Chapter 28</b> .....	<b>507</b>
Low Heritability in Pharmacokinetics of Talinolol: A Pharmacogenetic Twin Study on the Heritability of the Pharmacokinetics of Talinolol, a Putative Probe Drug of MDR1 and Other Membrane Transporters <i>by Johannes Matthaei, Mladen V. Tzvetkov, Valerie Gal, et al.</i>	
<b>Chapter 29</b> .....	<b>535</b>
Pharmacokinetics of Nalbuphine Hydrochloride Extended Release Tablets in Hemodialysis Patients with Exploratory Effect on Pruritus <i>by Amale Hawi, Harry Alcorn Jr, Jolene Berg, et al.</i>	
<b>Chapter 30</b> .....	<b>555</b>
Identification of Cryptolepine Metabolites in Rat and Human Hepatocytes and Metabolism and Pharmacokinetics of Cryptolepine in Sprague Dawley Rats <i>by Arnold Donkor Forkuo, Charles Ansah, David Pearson, et al.</i>	
<b>Chapter 31</b> .....	<b>575</b>
Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 403, a Human Anti-Nerve Growth Factor Monoclonal Antibody, in Two Phase I Studies with Healthy Volunteers and Knee Osteoarthritis Subjects <i>by Jason M. Gow, Wayne H. Tsuji, Gary J. Williams, et al.</i>	
<b>Chapter 32</b> .....	<b>597</b>
Combination Therapy in Cancer: Effects of Angiogenesis Inhibitors on Drug Pharmacokinetics and Pharmacodynamics <i>by Ilaria Fuso Nerini, Marta Cesca, Francesca Bizzaro, et al.</i>	
<b>Chapter 33</b> .....	<b>619</b>
Paracetamol Pharmacokinetics and Metabolism in Young Women	

*by Karel Allegaert, Mariska Y. Peeters, Bjorn Beleyn, et al.*

**Chapter 34.....641**

Pharmacokinetics and Safety of Carfilzomib in Patients with Relapsed Multiple Myeloma and End-Stage Renal Disease (ESRD): An Open-Label, Single-Arm, Phase I Study

*by Bruce E. Miller, Sunil Mistry, Kevin Smart, et al.*

**Chapter 35.....665**

Population Pharmacokinetics of Nintedanib, an Inhibitor of Tyrosine Kinases, in Patients with Non-Small Cell Lung Cancer or Idiopathic Pulmonary Fibrosis

*by Ulrike Schmid, Karl-Heinz Liesenfeld, Angele Fleury, et al.*

**Chapter 36.....693**

Efficacy, Safety and Pharmacokinetics of Simeprevir and TMC647055/Ritonavir with or without Ribavirin and JNJ-56914845 in HCV Genotype 1 Infection

*by Stefan Bourgeois, Hans Van Vlierberghe, Christophe Moreno, et al.*

**Chapter 37.....717**

The Influence of Nevirapine and Efavirenz-Based Anti-Retroviral Therapy on the Pharmacokinetics of Lumefantrine and Anti-Malarial Dose Recommendation in HIV-Malaria Co-Treatment

*by Betty A Maganda, Eliford Ngaimisi, Appolinary AR Kamuhabwa, et al.*

**Chapter 38.....743**

New Insights into the Pharmacokinetics and Pharmacodynamics of Natalizumab Treatment for Patients with Multiple Sclerosis, Obtained from Clinical and in Vitro Studies

*by T. Sehr, U. Proschmann, K. Thomas, et al.*

**Chapter 39.....767**

Pharmacokinetics of Antifungal Drugs: Practical Implications for Optimized Treatment of Patients

*by Romuald Bellmann and Piotr Smuszkiewicz*

## Chapter 1

# Pharmacokinetics of Ranitidine in Preterm and Term Neonates with Gastroesophageal Reflux

Ismael Lares Asseff<sup>1</sup>, Graciela Benitez Gaucin<sup>2</sup>, Hugo Juárez Olguín<sup>3</sup>,  
Jose Antonio Godinez Nájera<sup>1</sup>, Alejandra Toledo López<sup>3</sup>,  
Gabriela Pérez Guillé<sup>3</sup>, Fausto Zamura Torres<sup>1</sup>

<sup>1</sup>Interdisciplinary Centre of Investigation for Integral and Regional Development, Durango Unit, National Polytechnic Institute, Durango, Mexico

<sup>2</sup>Pediatrics and Neonatology Services, General Hospital of Durango, Durango, Mexico

<sup>3</sup>Laboratory of Pharmacology, National Institute of Pediatrics, and Department of Pharmacology, Faculty of Medicine, National Autonomous University of Mexico, Av Imán #1, 3er piso, Col Cuicuilco, CP 04530 Mexico City, Mexico

**Abstract: Background:** The aim of this study was to determine the effect of gestational age on pharmacokinetics of ranitidine in newborns with gastroesophageal reflux. **Methods:** A prospective, descriptive and pharmacokinetic study was carried out in 30 pre-term and 20 full-term babies. 3mg/kg of ranitidine was administered intravenously to all the babies and at 0.25, 0.5, 1, 2, 4, and 8h following the administration, samples of blood were drawn to assess ranitidine levels using high performance liquid chromatographic technique. **Results:** Pharmacokinetics of ranitidine had a bi-exponential behavior with a half-life elimination of ( $t_{1/2el}$ ) 2.79h, area under curve (AUC) of 1688ng/mL, volume of distribution (Vd) of 1.44L/kg, and clearance (Cl) of 5.9L/kg/h. The median plasmatic concentration in pre-terms

was 1113ng/mL and 280ng/mL in full-terms. Vd, t<sub>1/2</sub> and Cl presented high values in preterm although the correlation of Cl with glomerular filtration in term newborns was better. Conclusions: Plasma levels of ranitidine depend on the gestational age of the newborns. However, the possible relationship between after-birth age and pharmacokinetics of the neonates as their internal organs get matured without minding their gestational background.

**Keywords:** Gestational Age, Full-Term, Neonates, Pre-Term, Ranitidine, Pharmacokinetics

## 1. Background

Ranitidine decreases gastric acid secretion and improves esophagitis. It is then fundamental to have a good knowledge of its pharmacokinetic activities so as to make the best use of it in the treatment of every patient<sup>[1]-[4]</sup>. In normal newborns and infants, several organ systems progressively get matured to culminate in the later life and progressive maturation depends on the organ system and the specific iso-enzyme involved<sup>[5][6]</sup>. In a study by Hedenström et al.,<sup>[7]</sup>, on pharmacokinetics of ranitidine in adults, it was found that the use of multiple dosing scheme of ranitidine has similar parameters as the use of single dosing scheme. Its concentration, following intravenous administrations fits to a bi-exponential kinetics. In neonates, the half-life elimination is almost 2h, and it is a little more prolonged after oral administration<sup>[8]</sup>. Hepatic metabolism is one of the elimination route and this suggests that the drug has enterohepatic re-circulation for bi-exponential rate<sup>[9]</sup>.

Due to the high risk of either overdosing or under-dosing in newborns, which could lead to either therapeutic failure or toxic effect, the study of pharmacokinetics of ranitidine in this group of patients is very important<sup>[1][10][11]</sup>. The absence of specific ranitidine dosing scheme for newborns has cornered physicians to use doses obtained by modifying the dosing schemes for older and mature children. The result of this is usually overdosing or sub-therapeutic dosing scheme.

In a study of pharmacokinetics of ranitidine in 27 full-term newborns without liver or kidney problems using 2.4mg/kg of ranitidine, Fontana et al.,<sup>[12]</sup>, found that the half-life elimination (t<sub>1/2el</sub>) of the drug was 3.45 ± 0.31h, the total distribution volume (Vd) was 1.52 ± 0.91L/kg and the total plasmatic clearance (CL)